Concepedia

The feasibility, safety, and efficacy of Paxlovid treatment in SARS-CoV-2-infected children aged 6–14 years: a cohort study

Gangfeng Yan, Jianguo Zhou, Haitao Zhu, Yiwei Chen, Yanming Lu, Ting Zhang, Hui Yu, Libo Wang, Hong Xu, Zheng Wang,

Annals of Translational Medicine · 2022 · 34 citations · 10 references

DOIFull text

Open access

Abstract

Based on the current small sample size study, Paxlovid is a feasible option for treating SARS-CoV-2-infected children aged 6-14 years with underlying diseases. However, the safety and efficacy of Paxlovid warrant further large-scale studies.

References

10

An oral SARS-CoV-2 M <sup>pro</sup> inhibitor clinical candidate for the treatment of COVID-19

Dafydd R. Owen, Charlotte Allerton, Annaliesa S. Anderson et al. · Science · 2021 · 1.8K citations · Full text

, , +16

Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Replication in an Immunocompromised Patient

Ji Hoon Baang, Christopher Smith, Carmen Mirabelli et al. · The Journal of Infectious Diseases · 2020 · 330 citations · Full text

Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir

Irina F. Sevrioukova, T.L. Poulos · Proceedings of the National Academy of Sciences · 2010 · 283 citations · Full text

, , +18

Risk Factors for Severe COVID-19 in Children

Kelly Graff, Christiana Smith, Lori Silveira et al. · The Pediatric Infectious Disease Journal · 2021 · 278 citations

Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age

C. Buddy Creech, Evan J. Anderson, Vladimir Berthaud et al. · New England Journal of Medicine · 2022 · 170 citations · Full text